
浏览全部资源
扫码关注微信
1.400037 重庆,陆军军医大学(第三军医大学)第二附属医院神经内科
2.637000 四川 南充,川北医学院附属医院神经内科
3.400037 重庆,陆军军医大学(第三军医大学)第二附属医院临床医学研究中心
[王法祥,E-mail: faxiangwang@sina.cn WANG Faxiang, E-mail: faxiangwang@sina.cn
收稿:2023-12-19,
修回:2024-01-08,
纸质出版:2024-04-15
移动端阅览
滕灿, 余美玲, 蒋国会, 等. 两种海人酸癫痫小鼠模型的建立及比较研究[J]. 陆军军医大学学报, 2024,46(7):661-669.
Can TENG, Meiling YU, Guohui JIANG, et al. Establishment and comparison of 2 mouse models of kainic acid induced epilepsy[J]. Journal of Army Medical University, 2024, 46(7): 661-669.
滕灿, 余美玲, 蒋国会, 等. 两种海人酸癫痫小鼠模型的建立及比较研究[J]. 陆军军医大学学报, 2024,46(7):661-669. DOI: 10.16016/j.2097-0927.202312098.
Can TENG, Meiling YU, Guohui JIANG, et al. Establishment and comparison of 2 mouse models of kainic acid induced epilepsy[J]. Journal of Army Medical University, 2024, 46(7): 661-669. DOI: 10.16016/j.2097-0927.202312098.
目的
2
比较分析海人酸(kainic acid
KA)侧脑室(intracerebroventricular,ICV)注射和腹腔注射(intraperitoneal injections
IP)两种给药路径建立的颞叶癫痫小鼠模型早期的行为学和病理学差异。
方法
2
100只C57BL/6N野生型(wild type
WT)雄性小鼠(体质量为20~22 g),按随机数字表法分为4组:ICV+ normal saline(NS)对照组(
n
=10),ICV+KA模型组(
n
=40),IP+NS对照组(
n
=10),IP+KA模型组(
n
=40)。ICV+KA模型组使用600 nL的KA(0.5 mg/mL)进行侧脑室注射,IP+KA模型组按25 mg/kg剂量进行腹腔注射,对照组使用等量的生理盐水进行侧脑室
和腹腔注射。建立模型3 d后,进行行为学、分子生物学(Western blot)和神经病理损伤评估(FJB染色,TUNEL染色,免疫荧光染色)。
结果
2
两对照组无痫性发作,两模型组均出现痫性发作。IP+KA组与ICV+KA组死亡率分别为47.50%和65.00%,造模成功率分别为80.00%与60.00%。与IP+KA组比较,ICV+KA组小鼠模型成功率明显增高而死亡率明显减少。FJB染色和TUNEL染色结果显示,与IP+KA组比较,ICV+KA组海马的神经变性和凋亡改变程度变化更加明显(
P
<
0.05)。与IP+KA组比较,ICV+KA组海马凋亡蛋白表达差异也有统计学意义(
P
<
0.05)。免疫荧光结果显示,ICV+KA和IP+KA组海马和皮层的星形胶质细胞和小胶质细胞较对照组明显激活(
P
<
0.05)
但是ICV+KA组海马和皮层的胶质细胞激活程度均强于IP+KA组(
P
<
0.05)。ICV+KA组海马和皮层的GFAP和Iba-1蛋白表达均高于IP+KA组(
P
<
0.05)。
结论
2
两种KA制备方法均可制备出成功的癫痫模型。但ICV路径制备癫痫小鼠具有更高的成功率和更少的死亡率,并且神经病理损害程度和胶质细胞激活程度更加明显。
Objective
2
To investigate and analyze the behavioral and pathological differences in early-stage mouse models of epilepsy established by 2 different administration routes for kainic acid (KA)
intracerebroventricular (ICV) injection and intraperitoneal (IP) injection.
Methods
2
A total of 100 male C57BL/6N wild-type (WT) mice (20~22 g) were randomly divided into ICV+ normal saline (NS)control group(
n
=10)
ICV+KA model group(
n
=40)
IP+NS control group(
n
=10) and IP+KA model group (
n
=40). The ICV+KA model group was given 600 nL of KA (0.5 mg/mL)
via
ICV injection
and the IP+KA model group was injected with different dose of KA (25 mg/kg). Two control groups were administered equal volumes of NS
via
corresponding routes. After 3 d of modeling
the evaluation of behavioristics
molecular biology (including Western blotting)
and neuropathological assessments (including FJB staining
TUNEL staining and immunofluorescence staining) were performed.
Results
2
No epileptic seizures were observed in both 2 control groups
while exhibited seizures were observed in both model gro
ups. The mortality rates of the IP+KA group and the ICV+KA group were 47.50% and 65.00% respectively
while the success rates of modeling were 80.00% and 60.00% respectively. Compared with the IP+KA group
the ICV+KA group showed a significant increase in success rate and a significant reduction in mortality rate. FJB and TUNEL staining results showed that
compared with the IP+KA group
the severity of neurodegeneration and apoptotic changes in the hippocampus of the ICV+KA group were more significant (
P
<
0.05). Compared with the IP+KA group
there was also a significant difference in the expression of apoptotic proteins in the hippocampus of the ICV+KA group (
P
<
0.05). Immunofluorescence results showed that the astrocytes and microglia in the hippocampus and cortex of the ICV+KA and IP+KA groups were significantly activated compared with the control groups (
P
<
0.05)
but the activation of glial cells in the hippocampus and cortex of the ICV+KA group was stronger than that of the IP+KA model group (
P
<
0.05) and the activation levels in the ICV+KA group were higher than in the IP+KA model group (
P
<
0.01). Moreover
expression levels of GFAP and Iba-1 proteins in the hippocampus and cortex were higher in the ICV+KA group than the IP+KA group (
P
<
0.05).
Conclusion
2
Two routes of KA administration are effective in construct epilepsy models. The mice with ICV administration route show a higher success rate and lower mortality rate
and more significant neuropathological damage and glial cell activation.
FISHER R S, ACEVEDO C, ARZIMANOGLOU A, et al . ILAE Official Report: a practical clinical definition of epilepsy[J ] . Epilepsia, 2014, 55(4): 475-482. DOI: 10.1111/epi.12550.
THIJS R D, SURGES R, O'BRIEN T J, et al . Epilepsy in adults[J ] . Lancet, 2019, 393(10172): 689-701. DOI: 10.1016/S0140-6736(18)32596-0.
NELIGAN A, HAUSER W A, SANDER J W. The epidemiology of the epilepsies[J]. Handb Clin Neurol, 2012, 107: 113-133. DOI: 10.1016/B978-0-444-52898-8.00006-9.
KWAN P, BRODIE M J. Early identification of refractory epilepsy[J]. N Engl J Med, 2000, 342(5): 314-319. DOI: 10.1056/NEJM200002033420503.
KALILANI L, SUN X Z, PELGRIMS B, et al . The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis[J ] . Epilepsia, 2018, 59(1 2): 2179-2193. DOI: 10.1111/epi.14596.
WANG F X, YANG X L, MA Y S, et al . TRIF contributes to epileptogenesis in temporal lobe epilepsy during TLR4 activation[J ] . Brain Behav Immun, 2018, 67: 65-76. DOI: 10.1016/j.bbi.2017.07.157.
KEISER M S, CHEN Y H, DAVIDSON B L. Techniques for intracranial stereotaxic injections of adeno-associated viral vectors in adult mice[J]. Curr Protoc Mouse Biol, 2018, 8(4): e57. DOI: 10.1002/cpmo.57.
PIJET B, KONOPKA A, REJMAK E, et al . The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus[J ] . Sci Rep, 2020, 10: 21314. DOI: 10.1038/s41598-020-78341-y.
FERRARO T N, GOLDEN G T, SMITH G G, et al . Differential susceptibility to seizures induced by systemic kainic acid treatment in mature DBA/2J and C57BLl6J mice[J ] . Epilepsia, 1995, 36(3): 301-307. DOI: 10.1111/j.1528-1157.1995.tb00999.x.
BERGEY G K, MORRELL M J, MIZRAHI E M, et al . Long-term treatment with responsive brain stimulation in adults with refractory partial seizures[J ] . Neurology, 2015, 84(8): 810-817. D OI: 10.1212/wnl.0000000000001280.
DU K, HE M, ZHAO D Y, et al . Mechanism of cell death pathways in status epilepticus and related therapeutic agents[J ] . Biomed Pharmacother, 2022, 149: 112875. DOI: 10.1016/j.biopha.2022.112875.
SOKOLOVA T V, ZABRODSKAYA Y M, LITOVCHENKO A V, et al . Relationship between neuroglial apoptosis and neuroinflammation in the epileptic focus of the brain and in the blood of patients with drug-resistant epilepsy[J ] . Int J Mol Sci, 2022, 23(20): 12561. DOI: 10.3390/ijms232012561.
NABBOUT R, KUCHENBUCH M. Impact of predictive, preventive and precision medicine strategies in epilepsy[J]. Nat Rev Neurol, 2020, 16(12): 674-688. DOI: 10.1038/s41582-020-0409-4.
UPAGANLAWAR A B, WANKHEDE N L, KALE M B, et al . Interweaving epilepsy and neurodegeneration: vitamin E as a treatment approach[J ] . Biomed Pharmacother, 2021, 143: 112146. DOI: 10.1016/j.biopha.2021.112146.
SCHMUED L C, HOPKINS K J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration[J]. Brain Res, 2000, 874(2): 123-130. DOI: 10.1016/S0006-8993(00)02513-0.
VEZZANI A, RAVIZZA T, BEDNER P, et al . Astrocytes in the initiation and progression of epilepsy[J ] . Nat Rev Neurol, 2022, 18(12): 707-722. DOI: 10.1038/s41582-022-00727-5.
YU C, DENG X J, XU D. Microglia in epilepsy[J]. Neurobiol Dis, 2023, 185: 106249. DOI: 10.1016/j.nbd.2023.106249.
PURNELL B S, ALVES M, BOISON D. Astrocyte-neuron circuits in epilepsy[J]. Neurobiol Dis, 2023, 179: 106058. DOI: 10.1016/j.nbd.2023.106058.
VEZZANI A, DI SAPIA R, KEBEDE V, et al . Neuroimmunology of status epilepticus[J ] . Epilepsy Behav, 2023, 140: 109095. DOI: 10.1016/j.yebeh.2023.109095.
CHEN Y, NAGIB M M, YASMEN N, et al . Neuroinflammatory mediators in acquired epilepsy: an update[J ] . Inflamm Res, 2023, 72(4): 683-701. DOI: 10.1007/s00011-023-01700-8.
0
浏览量
418
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621